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Abstract Protamines are polycationic proteins that are widely 
used for neutralisation of the anticoagulant action of heparin. 
However, several reports have shown adverse, mast cell- 
dependent reactions to protamine. The exact mechanism by 
which protamine causes these adverse effects is not clear. In the 
present study, the possibility that protamine may influence mast 
cell chymase function was investigated. Mast cell chymase is in 
vivo recovered in a macromolecular complex with heparin 
proteoglycan, and this interaction is essential for expression of 
optimal enzymatic activity. Protamine was shown to strongly 
reduce the activity of mast cell chymase by a mechanism that 
involved displacement of the chymase from heparin proteoglycan. 
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1. Introduction 
Protamines are small polycationic proteins that have wide- 
spread clinical use in the reversal of heparin anticoagulation. 
In addition, protamines are often added to insulin prepara- 
tions in order to improve the pharmacological properties of 
the hormone. A number of reports have shown that prota- 
mine can cause adverse reactions. These range from mild re- 
actions such as rash and urticaria to more severe conditions 
including anaphylaxis, bronchospasm and cardiovascular col- 
lapse [1]. The mechanism(s) by which protamine causes these 
adverse reactions is not clear. Several reports suggest that 
elevated serum levels of IgE or IgG to protamine increase 
the risk of obtaining adverse reactions to the protein [2,3]. 
Other reports have shown that protamine can interact directly 
with mast cells (MC), causing non-immunological histamine 
release [4,5]. In addition, inhibition of plasma carboxypepti- 
dase N [6] and activation of the complement system [7,8] by 
protamine have been reported. 
The importance of MC in various hypersensitivity reactions 
is well established [9]. When MC are activated they release 
different inflammatory mediators such as histamine, cyto- 
kines, heparin proteoglycan (PG), carboxypeptidase and ser- 
ine proteases [10,11]. The serine proteases are either tryptases 
(trypsin-like substrate specificities) or chymases (chymotryp- 
sin-like substrate specificities). Although the exact physiologi- 
cal function(s) of the MC chymases is not known, different 
identified substrates for these enzymes [12-15] indicate the 
potential involvement in a variety of processes related to the 
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Abbrev&tions: MC, mast cell; PBS, phosphate-buffered saline; PG, 
proteoglycan; RMCP-, rat mast cell protease. 
inflammatory response. The chymases are in vivo strongly 
bound to heparin PG [16-19] and the association with heparin 
is necessary for the chymases to express optimal activity to- 
wards various substrates [13-15,20]. Since protamine is known 
to bind strongly to heparin I hypothesised that protamine, by 
interfering with the binding of chymase to heparin PG, could 
influence the activity of the protease. Indeed, in the present 
report it is shown that protamine strongly reduces the activity 
of MC chymase. Possibly, this observation can be related to 
the various adverse reactions caused by protamine. 
2. Materials and methods 
Rat mast cell protease 1(RMCP-1) (EC 3.4.21.39) and heparin PG 
were purified from rat peritoneal MC by a combination of anion 
exchange chromatography on DEAE-Sephacel and HPLC on a 
Superdex 75 column as described [18]. Heparin from pig intestinal 
mucosa was a gift from Ulf Lindahl, Uppsala University, Dept. of 
Medical and Physiological Chemistry, Uppsala, Sweden. The chromo- 
genic peptide substrates S-2586 (MeO-Suc-Arg-Pro-Tyr-pNA) and S- 
2238 (H-D-Phe-Pip-Arg-pNA) were from Chromogenix (M61ndal, 
Sweden). Protamine isolated from Salmon was purchased from Sigma. 
Bovine ~-thrombin was a gift from I. Bj6rk, Dept. of Veterinary 
Medical Chemistry, Uppsala, Sweden. DEAE-cellulose (DEAE-Se- 
phacel) was purchased from Pharmacia (Uppsala, Sweden). 
2.1. Enzymatic assays 
RMCP-1 activities were measured in 96-well microtiter plates. 
RMCP-1 (25-50 ng) was diluted with phosphate-buffered saline 
(PBS)/0.1% Triton X-100 to a final volume of 200 ~tl. In standard 
conditions, enzyme activity was detected after addition of 20 txl of a 
solution (4 mM in H20) of the chromogenic chymotrypsin substrate 
S-2586, and monitoring of the absorbance at405 nm with a Titertek 
Multiscan spectrophotometer (Flow Laboratories). Alternatively, 
when thrombin was used as substrate for RMCP-1, 10 ng of thrombin 
was added to wells containing RMCP-1, followed by an additional 15 
min incubation time and monitoring of residual thrombin activity 
after addition of 20 ~tl of a solution (2.5 mM in H20) of the chromo- 
genic thrombin substrate S-2238. In experiments where the effect of 
various heparins on RMCP-1 activity was studied, the polysaccharides 
were added 15 min prior to addition of the chymase substrate. In 
standard incubations a 2.5:1 ratio (w/w) of RMCP-1/heparin PG 
was used. This protein/PG ratio was chosen to give optimal potentia- 
tion of RMCP-1 activity (see inset in Fig. 2A). The effect of prota- 
mine on chymase activity was determined after the addition of in- 
creasing amounts of protamine to RMCP-1/heparin mixtures or to 
free RMCP-1, followed by an additional incubation time of 15 min 
and monitoring of residual enzymatic activities as above. The Km and 
kcat values for RMCP-l-catalysed hydrolysis of S-2586 were deter- 
mined from initial rate measurements, followed by non-linear regres- 
sion analysis. 
Peritoneal MC were purified and cultured as described [18,21]. In 
experiments where the thrombin-inactivating activities of intact MC 
were determined, 1 x 104 purified MC (in 10 p.l) were incubated in400 
I11 of cell culture medium. Thrombin (100 ng) was added and samples 
(20 Ixl) from the media were collected at 10, 20, 30, 60 and 90 min. 
The samples were mixed with 200 111 of PBS and were analysed for 
residual thrombin activities. The effect of protamine on thrombin 
inactivation was studied after preincubating the cells for 15 min 
S0014-5793196/$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
SSDIS0014-5793(96)00239-6  
G Pejler/FEBS Letters 383 (1996) 170-174 171 
with protamine before addition of thrombin. The S-2586-cleaving ac- 
tMties of intact MC were determined after mixing of 1 x 10 4 MC (in 
1(1 tal) with 100 gl PBS in 96-well microtiter plates. 20 tal of an S-2586 
solution (4 mM in H20) was added followed by monitoring of the 
absorbance at 405 nm. The effect of protamine was determined after 
preincubation (15 min) of the MC with the compound followed by the 
addition of S-2586. Cellular extracts were obtained after solubilisation 
o~ l X 106 MC with 5 ml of PBS/0.5% Triton X-100. 
2. '. DEAE-cellulose precipitation assay 
50 ng of RMCP-1 was incubated in the absence or presence of 20 
n~ of heparin PG, and various amounts of protamine. Incubations 
w, re performed in 1.5 ml Eppendorf tubes in a volume of 600 gl of 
PBS/0.1% Triton X-100. After 20 rain, 400 tal of a 1:1 mixture of 
DEAE-Sephacel and PBS/0.1% Triton X-100, or 400 gl of PBS/ 
0. % Triton X-100 was added followed by gentle mixing of the tubes 
(eTtd over end) for 30 min. The gels were allowed to settle and 200 l.tl 
o! the resulting supernatants were transferred to 96-well plates, fol- 
Io,red by determination of residual RMCP-1 activity using the chro- 
m,)genic substrate S-2586 (see above). In some experiments 1 pg of 
hc~arin PG had been added to the wells before transferring of the 
su ~ernatants. 
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Fig. l. Regulation of chymase activity expressed by intact MC and 
M(; extracts. (A) Intact MC (1 × 104; e) or MC extracts (5 tal, cor- 
responding to 1 x 103 cells; G) were preincubated with the amounts 
of protamine indicated. After 15 rain, residual RMCP-1 activities 
tm~ards S-2586 were determined. Results are expressed as % of the 
acl:vity compared with chymase activity in the absence of prota- 
mine. (B) Protamine at the amounts indicated was added to 1 x 104 
MCL After 15 rain, 100 ng of thrombin was added followed by 
monitoring of thrombin inactivation. No detectable inactivation of 
thr,)mbin was observed in the absence of MC. 
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Fig. 2. Regulation of RMCP-I by protamine. RMCP-1 (25 ng) was 
incubated in the presence of 10 ng of heparin PG (o), 10 ng of pig 
mucosal heparin (O) or without heparin (i). After 15 rain, prota- 
mine at the amounts indicated was added. (A) After an additional 
15 min, residual RMCP-1 activities towards S-2586 were measured. 
(B) After 15 min, 10 ng of thrombin was added followed by the de- 
termination of thrombin-inactivating activity. The inset in (A) shows 
the potentiation of RMCP-1 (25 ng) by heparin PG. 
3. Results 
We have previously shown that purified rat peritoneal MC 
express chymase activity that is bound to the cell surface, and 
that the surface-associated chymase is a potent inactivator of 
thrombin [18]. The inactivation of thrombin involves degrada- 
tion of the coagulation enzyme [22]. Experiments were per- 
formed to investigate if protamine could influence the chy- 
mase activity expressed on intact MC, using both the 
chromogenic peptide substrate S-2586 and thrombin as sub- 
strates for the chymase. The results showed that protamine 
decreased chymase activity towards both S-2586 (Fig. 1A) and 
thrombin (Fig. 1B). In addition, protamine decreased chymase 
activity present in cellular extracts (Fig. 1A). When thrombin 
was used as substrate, 100% inhibition of chymase activity 
was readily achieved whereas ,~25% of the activity towards 
S-2586 (both on intact MC and in MC extracts) was resistant 
to regulation by protamine. Maximal reduction of chymase 
activity was obtained at 1 gg of added protamine, both when 
thrombin and S-2586 were employed as substrates for the 
chymase. 
RMCP-1 is the major chymase expressed by rat peritoneal 
MC [23], and experiments were performed to determine 
whether protamine could regulate the activity of purified 
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RMCP-1. In vivo, RMCP-1 is recovered in a tight macromo- 
lecular complex with heparin PG and we have previously 
shown that heparin strongly potentiates the activity of the 
enzyme [18,20]. It is thus appropriate to use the RMCP-1/ 
heparin PG complexes, rather than the free chymase, as tar- 
gets for regulation by protamine. The amount of heparin PG 
added to RMCP-1 was chosen to give optimal stimulation of 
enzyme activity (see inset in Fig. 2A). Protamine did not show 
any significant inhibition of S-2586 hydrolysis by free RMCP- 
1, whereas the activity of RMCP-1 present in complex with 
either heparin PG or pig mucosal heparin ('commercial hepar- 
in') was reduced by protamine, both using thrombin and S- 
2586 as RMCP-1 substrates (Fig. 2). Again, protamine gave 
essentially complete inhibition of the thrombin-inactivating 
activity of RMCP-1 whereas a portion (,~ 37%) of the activity 
against S-2586 was resistant to regulation by protamine. The 
level of RMCP-1 activity towards S-2586 that was resistant to 
regulation was similar to the amount of activity expressed by 
the free chymase, indicating that protamine acts by displacing 
RMCP-1 from heparin PG. When increased amounts of he- 
parin PG was added to RMCP-1 the effect of protamine was 
partially blocked, with greater amounts of protamine being 
required to obtain reduction of the chymase activity (Fig. 
3). The time coarse for the regulation showed that the process 
was very rapid, with maximal decrease in activity being 
achieved within 1 min (Fig. 4). 
To obtain direct evidence for displacement of RMCP-1 
from heparin PG by protamine, an assay involving precipita- 
tion of RMCP-1/heparin PG complexes by an anion exchange 
resin, DEAE-cellulose, was developed. RMCP-1 was incu- 
bated either alone, together with heparin PG or in the pres- 
ence of both heparin PG and protamine. DEAE-cellulose was 
added to the incubation mixtures followed by the determina- 
tion of residual RMCP-1 activities in the resulting superna- 
tants. In the absence of heparin PG no significant precipita- 
tion of RMCP-1 activity by DEAE-cellulose was observed 
(Fig. 5). When heparin PG was added to RMCP-1, as ex- 
pected (see inset in Fig. 2A), a ,~ 3-fold increase in enzymatic 
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Fig. 3. Effect of heparin PG on the regulation of RMCP-1 by pro- 
tamine. RMCP-1 (25 ng) was incubated in the presence of 10 ng 
(e), 50 ng ((3) or 200 ng (m) of heparin PG. After 15 min, prota- 
mine at the concentrations indicated was added and after an addi- 
tional incubation time of 15 min, residual RMCP-I activities to- 
wards S-2586 were measured. The broken line represents RMCP-I 
activity in the absence of both heparin PG and protamine. 
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Fig. 4. Time course for the regulation of RMCP-I by protamine. 
RMCP-1 (25 ng) was incubated together with 10 ng of heparin PG. 
After 15 min, protamine (50 ng) was added and after the times indi- 
cated residual RMCP-1 activity towards S-2586 was determined. 
The broken line represents RMCP-1 activity in the absence of both 
heparin PG and protamine. 
activity was observed, and the majority of this activity was 
precipitated following the addition of DEAE-cellulose. These 
results thus indicate that heparin PG is bound to the DEAE- 
cellulose and that the observed reduction of RMCP-1 activity 
in the supernatants i  due to binding of the chymase to the 
DEAE-cellulose-associated heparin PG. Addition of prota- 
mine to the RMCP-1/heparin PG complexes resulted in in- 
creased recovery of RMCP-1 activity in the supernatants ob- 
tained after DEAE-cellulose precipitation, indicating 
displacement of RMCP-1 from the PG (Fig. 5). The maximal 
amount of RMCP-1 activity that could be recovered in the 
supernatants after addition of protamine corresponded to the 
level of activity displayed by the free chymase. If the chymase 
activity obtained in the supematants after addition of prota- 
mine is due to free RMCP-1, it should be possible to increase 
its activity by addition of heparin PG. Addition of excess 
amounts of heparin PG to the RMCP-1 recovered after dis- 
placement by protamine resulted in ,~2.7-fold enhancement 
of chymase activity, strongly indicating that the recovered 
RMCP-1 was indeed present in a free form (Fig. 5). In con- 
trast, RMCP-1 that had been previously incubated with he- 
parin PG in the absence of protamine was, as expected (see 
inset in Fig. 2A), not stimulated further by addition of excess 
amounts of heparin PG (Fig. 5). 
The Km and kcat values of RMCP-1 for S-2586 were deter- 
mined for the free chymase, chymase in complex with heparin 
PG and for RMCP-1/heparin PG complexes in the presence of 
protamine (Table 1). Heparin PG induced a ~ 5-fold decrease 
in the Km of RMCP-1 for S-2586, whereas no significant effect 
on the kc~t value was observed. When protamine was added to 
the RMCP-1/heparin PG complexes the Km value was in- 
creased back to approximately the same level as that displayed 
by the free chymase, without any significant effect on the kc~t 
value. 
4. Discussion 
The interaction of MC chymases with heparin PG influ- 
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Table 1 
Kinetic constants of RMCP-1 for S-2586 in the presence of heparin PG and protamine ~ 
173 
Km (mM) kcat (S -1) kcatlKm (M -I s -1) 
w/o heparin PG 1.6 + 0.2 9.5 + 0.4 5.9 × 103 
+]0 ng heparin PG 0.31 + 0.03 7.8 _+ 0.2 25 × 103 
+!0 ng heparin PG, 
+50 ng protamine 2.0 + 0.2 10.4 _+ 0.5 5.2 × 103 
a75 ng of RMCP-1. For further experimental details see section 2. 
elces the proteases in several ways. Firstly, heparin potenti- 
ales the activity of the enzymes by a mechanism that appears 
t~ involve a reduction of the Km of the proteases for their 
st bstrates [20]. Secondly, heparin PG-bound chymase tends to 
remain associated with the MC surface after cellular degranu- 
la:ion [17,18]. Thirdly, we have recently shown that RMCP-1 
b,,und to heparin PG is largely resistant o inhibition by a 
v:~riety of plasma protease inhibitors such as cq-antitrypsin, 
c~ -antichymotrypsin and c~2-macroglobulin [20]. Since 
R VICP-1 associated with heparin PG appears to be resistant 
tc inhibition by conventional protease inhibitors I hypothe- 
si,,ed that heparin antagonists, by interfering with the binding 
o~ chymase to PG, could act as regulators of the MC pro- 
teises. Indeed, in the present study it is shown, to my knowl- 
e~4ge for the first time, that protamine, a heparin antagonist, 
st ongly decreases the activity of MC chymase present in com- 
pJ ~-x with heparin PG. The mechanism of regulation is shown 
tc involve displacement of the chymase from its physiological 
li~and, heparin PG. The physiological inhibitors of MC chy- 
m ~ses have not yet been identified. However, considering the 
redstance of these enzymes to inhibition by conventional pro- 
terse inhibitors, a regulation pathway involving heparin an- 
tagonists uch as protamine-like proteins, vitronectin [24] or 
la:toferrin (G. Pejler, unpublished observation) may be of 
pJ~ysiological significance. 
It is important to emphasise that the dissociation of 
R VICP-1 from heparin PG caused by protamine does not 
result in destruction of the active site of the chymase. 
A though free RMCP-1 is essentially completely devoid of 
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Fi;. 5. Precipitation of RMCP-1/heparin PG with DEAE-cellulose. 
RMCP-1 (50 ng) was incubated alone (-PG) or together with 20 
ng of heparin PG (+PG) and protamine as indicated. After 20 min, 
40,) i.tl of a i :1 mixture of DEAE-Sephacel and PBS/0.1% Triton X- 
101 (+DEAE), or 400 ~tl of PBS/0.1% Triton (-DEAE) was added, 
followed by the determination f residual RMCP-1 activity present 
in the resulting supernatants (hatched bars). 1 j.tg of heparin PG 
was added as indicated (---)+1 ~tg PG; closed bars) to RMCP-1 that 
had been previously incubated with 20 ng of heparin PG, or to 
supernatants from tubes where RMCP-1 had first been incubated 
together with 20 ng heparin PG and protamine followed by precipi- 
tation with DEAE-Sephacel. 
activity when thrombin is used as substrate, it still expresses 
significant activity towards S-2586. In addition, reconstitution 
of the chymase with optimal amounts of heparin PG results in 
an increase in activity back to the same level as that of the 
original RMCP-1/heparin PG complex. The fate of the free 
chymases released after dissociation from the PG is uncertain. 
Clearly, the dissociation process would facilitate diffusion of 
the chymases away from the MC surface and allow the chy- 
mases to exert their action (although being less active) at 
other sites in the body. Alternatively, released chymases may 
be rapidly neutralised by various protease inhibitors. 
Due to the evolution of new techniques in surgery the use 
of protamine in the reversal of heparin anticoagulation has 
increased over the last decade. Along with the increased use of 
protamine, increased numbers of adverse reactions associated 
with i.v. protamine administration have been reported. In 
order to improve the strategy for protamine treatment i  is 
necessary to understand the mechanisms by which protamine 
causes these adverse reactions. It is well established that IgE 
and IgG to protamine constitute major risk factors for devel- 
oping adverse reactions to protamine [1]. However, the iden- 
tification of several apparently immunoglobulin-independent 
effects of protamine [4-6,8] indicates that the mechanism of 
action may be complex. Since protamine is an established 
heparin antagonist in vivo it is plausible that the compound 
will interact with endogenous chymase/heparin PG complexes, 
thereby decreasing the heparin-dependent ac ivities displayed 
by the proteases. When predicting the potential in vivo effects 
of chymase regulation by protamine it is therefore necessary 
to consider those activities of MC chymases that are influ- 
enced by heparin. For instance, the effect of protamine on 
the capacity of RMCP-1 to inactivate thrombin may indeed 
be relevant in relation to the regulation of the inflammatory 
response. Extravascular ctivation of the coagulation cascade, 
accompanied by thrombin formation, is a common feature of 
various inflammatory reactions, including immediate hyper- 
sensitivity [25]. Thrombin has, in addition to its procoagulant 
activities, a number of properties of potential importance in 
inflammation, e.g. chemotactic activity [26], mitogenic activity 
[27] and capacity to induce MC degranulation [28]. Thus, the 
blocking of chymase-mediated hrombin inactivation may in- 
crease the pro-inflammatory effects of generated thrombin, 
thereby contributing to the adverse ffects observed for pro- 
tamine. Further, it has previously been shown that MC chy- 
mase has the ability to degrade anaphylatoxin C3a, by a me- 
chanism that is dependent on heparin PG [13]. Dissociation of 
the chymase from heparin PG by protamine would conse- 
quently result in a reduced capacity of the MC protease to 
inactivate C3a, and would lead to accumulation of the ana- 
phylatoxin in the tissue. Clearly, subsequent MC and basophil 
activation caused by C3a would contribute to the clinical 
symptoms observed in patients that show adverse reactions 
to protamine. 
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